Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Accumulated Expenses (2016 - 2025)

Veracyte (VCYT) has disclosed Accumulated Expenses for 14 consecutive years, with $48.8 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 11.35% to $48.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $48.8 million through Dec 2025, up 11.35% year-over-year, with the annual reading at $48.8 million for FY2025, 11.35% up from the prior year.
  • Accumulated Expenses hit $48.8 million in Q4 2025 for Veracyte, up from $48.4 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $48.8 million in Q4 2025 to a low of $16.3 million in Q1 2021.
  • Historically, Accumulated Expenses has averaged $36.2 million across 5 years, with a median of $36.9 million in 2022.
  • Biggest five-year swings in Accumulated Expenses: skyrocketed 237.25% in 2021 and later fell 20.5% in 2023.
  • Year by year, Accumulated Expenses stood at $39.5 million in 2021, then fell by 4.31% to $37.8 million in 2022, then increased by 1.73% to $38.4 million in 2023, then rose by 14.05% to $43.8 million in 2024, then rose by 11.35% to $48.8 million in 2025.
  • Business Quant data shows Accumulated Expenses for VCYT at $48.8 million in Q4 2025, $48.4 million in Q3 2025, and $43.7 million in Q2 2025.